Epigenetic targeting therapies to overcome chemotherapy resistance

Curt Balch, Kenneth Nephew

Research output: Chapter in Book/Report/Conference proceedingChapter

17 Citations (Scopus)

Abstract

It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of stemness signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
Pages285-311
Number of pages27
Volume754
DOIs
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume754
ISSN (Print)00652598

Fingerprint

Chemotherapy
Epigenomics
Tumors
Drug Therapy
Biomarkers
Stem cells
Aberrations
Neoplasms
Screening
Neoplastic Stem Cells
Therapeutics
Pharmaceutical Preparations
Signal Transduction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Balch, C., & Nephew, K. (2013). Epigenetic targeting therapies to overcome chemotherapy resistance. In Advances in Experimental Medicine and Biology (Vol. 754, pp. 285-311). (Advances in Experimental Medicine and Biology; Vol. 754). https://doi.org/10.1007/978-1-4419-9967-2-14

Epigenetic targeting therapies to overcome chemotherapy resistance. / Balch, Curt; Nephew, Kenneth.

Advances in Experimental Medicine and Biology. Vol. 754 2013. p. 285-311 (Advances in Experimental Medicine and Biology; Vol. 754).

Research output: Chapter in Book/Report/Conference proceedingChapter

Balch, C & Nephew, K 2013, Epigenetic targeting therapies to overcome chemotherapy resistance. in Advances in Experimental Medicine and Biology. vol. 754, Advances in Experimental Medicine and Biology, vol. 754, pp. 285-311. https://doi.org/10.1007/978-1-4419-9967-2-14
Balch C, Nephew K. Epigenetic targeting therapies to overcome chemotherapy resistance. In Advances in Experimental Medicine and Biology. Vol. 754. 2013. p. 285-311. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-9967-2-14
Balch, Curt ; Nephew, Kenneth. / Epigenetic targeting therapies to overcome chemotherapy resistance. Advances in Experimental Medicine and Biology. Vol. 754 2013. pp. 285-311 (Advances in Experimental Medicine and Biology).
@inbook{ca5e9619c02d4a47903b9b3a12d387e6,
title = "Epigenetic targeting therapies to overcome chemotherapy resistance",
abstract = "It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of stemness signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.",
author = "Curt Balch and Kenneth Nephew",
year = "2013",
doi = "10.1007/978-1-4419-9967-2-14",
language = "English",
isbn = "9781441999665",
volume = "754",
series = "Advances in Experimental Medicine and Biology",
pages = "285--311",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Epigenetic targeting therapies to overcome chemotherapy resistance

AU - Balch, Curt

AU - Nephew, Kenneth

PY - 2013

Y1 - 2013

N2 - It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of stemness signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.

AB - It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of stemness signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.

UR - http://www.scopus.com/inward/record.url?scp=84869064386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869064386&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-9967-2-14

DO - 10.1007/978-1-4419-9967-2-14

M3 - Chapter

C2 - 22956507

AN - SCOPUS:84869064386

SN - 9781441999665

VL - 754

T3 - Advances in Experimental Medicine and Biology

SP - 285

EP - 311

BT - Advances in Experimental Medicine and Biology

ER -